Thiazolidinediones as a privileged structural scaffold in PPAR agonists: A review
DOI:
https://doi.org/10.7439/ijpc.v6i5.3287Abstract
Thiazolidinediones are a versatile scaffold of connecting various classes of organic compounds with a unique structural feature of hydrogen bonding donor and the hydrogen bonding acceptor region. An extensive number of research has been carried out on thiazolidinedione derivatives as a potent class of PPAR-? agonists. The present review focuses on the chemistry and PPAR- agonistic activity of diverse classes of phenyl and heterocyclic based thiazolidinedionesDownloads
References
American Diabetes Association. (1996). How lab tests show you have diabetes. Diabetes Info. Retrieved June 18, 1997.
American Diabetes Association. (1997). Clinical practice recommendations: Self- monitoring of blood glucose. Diabetes Care. S (62). Retrieved July 14, 1997.
American Diabetes Association. (1997). Diabetes facts and figures. Retrieved June 18, 1997.
American Association of Diabetes Educators. (2003). A Core Curriculum for Diabetes Education (5th ed.). Chicago: AADE.
Lehmann JM, Moore LB, Smith-Oliver TA, et al: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
Einhorn D, Kipnes M, Glazer NB, et al: Durability of glycemic control with pioglitazone in long-term combination and monotherapy. Diabetes 2001; 50 (Suppl): A111.
Parulkar AA, Pendergrass ML, Granda-Ayala R, et al: Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
AVANDIA (rosiglitazone maleate): Prescribing information, 2005, GlaxoSmithKline.
ACTOSR (pioglitazone hydrochloride): Prescribing information, Takeda Pharmaceuticals America, Inc.
Scheen AJ: Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 305-313.
Berger J, Moller DE: The mechanisms of action of PPARs. Annu
Rev Med 2002; 53: 409 -435.
Chawla A, Repa JJ, Evans RM, et al: Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866- 1870.
Chinetti G, Fruchart JC, Staels B: Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49: 497-505.
Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
Luquet S, Lopez-Soriano J, Holst D, et al: Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 2004; 86: 833-837.
Marx N, Duez H, Fruchart JC, et al: Peroxisome proliferator activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94: 1168-1178.
Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
Malik S, Upadhyaya P, Miglani S. Thiazolidinediones: A plethro of biological load. International Journal of PharmTech Research. 2011, 3, 62-75.
Ahmed A. Elhenawy, Abeer A. A. Salama, Mahmoud M. Abdel All, Abdulaziz A. Alomri, H.S. Nassar: Synthesis, Characterization and Discovery Novel Anti-diabetic and Anti-hyperlipidemic Thiazolidinedione Derivatives. Int. J. Pharm. Sci. Rev. Res., 31(2): 23-30.
Roy. A, Bhanwase. A and Patil T.D. Synthesis and evaluation of some novel 5-[4-(substituted) benzylidene] 2.4 thiazolidinediones as oral antihyperglycemic agents. Research Journal of Pharmaceutical, Biological and Chemical Sciences 3 (3): 452-467.
Shashikant. R, Pattana, Prajact Kekareb, Ashwini Patil, Ana Nikaljec, Kittur. Studies on the synthesis of novel 2,4-thiazolidinedione Derivatives with antidiabetic activity. Iranian Journal of Pharmaceutical Sciences Autumn 2009: 5(4): 225-230.
Ashish, AL-Hazimi, Monirah A and Al-Alshaikh. Synthesis and study of (5Z)-5-[(4-oxo-4H-chromen-3-yl) methylidene]-1, 3-thiazolidine-2, 4-dione derivatives. Journal of Saudi Chemical Society 2010; 14: 373
Shriram. S. Purohit and Veerapur V.P. Benzisoxazole containing thiazolidinediones as peroxisome proliferator activated receptor-? agonists: design, molecular docking, synthesis & antidiabetic studies. Sch. Acad. J. Pharm., 2014; 3(1): 26-37.
Partha Neogi, Caixia Wang, Cuilian Xu, Guoyu Yang, Sufang Fan, Li Xin and Tingting Guo synthesized and studied number of 2, 4-thiazolidinedione derivatives of -phenyl substituted cinnamic acid for their PPAR agonist activity. Molbank 2014.
Debarshi Kar Mahapatra, Vivek Asati and Sanjay Kumar Bharti. Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives. European Journal of Medicinal Chemistry 2015; 92: 839-865.
Mohd imran, Milan Cacic, Mladen Trkovnik, Frane Cacic and Elizabeta Has-Schon review of recent thiazolidinediones as antidiabetics. Molecules 2006: 11: 134-147.
Shriram s.purohit and Veerapur V.P. Predicting the possibility of novel 5-substituted benzisoxazole Containing thiazolidine-2, 4-dione derivatives as potent ppar-? agonists. Int J Pharm Bio Sci 2012; 3(4): 142
HongWoo Lee, Sandip Sen, Biplab De and Trichy Siva Easwari synthesis and antidiabetic activity of novel substituted pyrimidines. Tropical Journal of Pharmaceutical Research 2014; 13 (9): 1445-1454.
Snehlata Jaiswal, Narsingh Sachan, Pooja Chawla And I.R. Pitta Synthesized A Novel Set Of Acridinylidene Thiazolidinediones And Benzylidene Thiazolidinediones. Journal Of Chemical And Pharmaceutical Sciences Volume 6 Issue 3 2005.
Devi Prasad Sahu, Kishor Arora and Anu Parmar synthesize and evaluation of thiazolidine-2,4-dionesderivatives for antihyperglycemic activity. Journal of Applied Chemistry 2004; 6 (1):10-24.
Robert T. Nolte, G. Bruce Wisely, Stefan Westi, Jeffery E. Cobb, Millard H. Lambert, Riki Kurokawa, Michael. G, Rosenfeldk, Timothy. M, Willson, Christopher. K. Glass & Michael. V and Milburn. Ligand binding and co-activator Assembly of the peroxisome Proliferator-activated receptor-g. Nature 1998; 395 (10): 137-143.
Schmidt A, Endo N, Rutledge S, Vogel R, Shinar D. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Molecular Endocrinology. 1992; 6: 41-49.
Sachin Malik, Prabhat Kumar Upadhyaya and Sandeep Miglani. Thiazolidinediones: A Plethro of Biological Load. International Journal of PharmTech Research; 3(1): 62-75.
Sharma P, Jain P, Pawar R. Design, synthesis and biological evaluation of some dual acting novel thiazolidindione derivatives. International Journal of Drug Design and Discovery. 2010; 1: 124-135.
Shashikant. R, Pattana, Prajact Kekareb, Ashwini Patil, Ana Nikaljec, Kittur. Studies on the synthesis of novel 2,4-thiazolidinedione Derivatives with antidiabetic activity. Iranian Journal of Pharmaceutical Sciences Autumn 2009: 5(4): 225-230.
Sher T, Yi HF, McBride OW, Gonzalez FJ. "cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor". Biochemistry 1993; 32 (21): 5598
Shriram S. Purohit, Abhinandan Alman and Jyoti Shewale. Synthesis & antimicrobial activity of a new series of 3, 5-disubstituted thiazolidine-2, 4-diones. Int J Pharm Pharm Sci, 4 (3): 273-276.
Srikanth L, Raghunandan N, Srinivas P, Reddy G. Synthesis and evaluation of newer quinoline derivatives of thiazolidinediones for their antidiabetic activity. International Journal of Pharma and Bio Sciences. 2010; 1: 120-131.
K. Sudheer Kumar, B. Madhava Reddy, V. Harinadha Babu. Synthesis Of Some Novel 2, 4-Thiazolidinedione Incorporated Pyrazole Derivatives As Anti Cancer Agents. Int J Pharm Pharm Sci, 6 (2): 831-834.
Suh M, Park S, Jee H. Comparison of QSAR Methods (CoMFA, CoMSIA, HQSAR) of Anticancer 1-N-Substituted Imidazoquinoline-4,9-dione Derivatives. Bull. Korean Chem. Soc. 2002; 23: 417-422.
Sumanasekera WK, Tien ES, Turpey R, Vanden Heuvel JP, Perdew GH. "Evidence that peroxisome proliferator-activated receptor alpha is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2". J. Biol. Chem. 2003; 278 (7): 4467
Suvitha Syam, Siddig Ibrahim Abdelwahab, Mohammed Ali Al-Mamary and Syam Mohan. Synthesis of Chalcones with Anticancer Activities. Molecules 2012; 17: 6179-6195.
Tuckerman ME, Martyna GJ. Understanding Modern Molecular Dynamics: Techniques and Applications. J. Phys. Chem. B. 2000, 104: 159-178.
Vaibhav A. Dixit and Prasad V. Bharatam. SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated Receptor
Werner J. Geldenhuys A, Max O. Funk B, Kendra F. Barnes A, Richard T. Carroll. Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoneet. Bioorganic & Medicinal Chemistry Letters 2010; 20: 819
Zoete V, Grosdidier A. Peroxisome proliferator activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim & Biophysical Acta. 2007; 8: 915
Rajeev Verma, Pooja Chawla and Shailendra K. Saraf. Syntheses, characterization and evaluation of some 1,3,4-tri substituted-5- pyrazolone derivatives as dual anti-inflammatory and antimicrobial agents. Der Pharmacia Sinica, 2012; 3 (5): 546-555.
Ravinder.S, Bhatti Manjit Singh and Jagir S. Sandhu. Microwave enhanced synthesis of 5-arylidene rhodanine under solvent free conditions using bismuth trichloride as a promoter. Rasayan J. Chem. 2008; 1(4): 738-742.
Rekha S, Shantharam U, Chandy V. Synthesis and evaluation of novel thiazolidinedione for anti-inflammatory agents. International Research Journal of Pharmacy. 2011; 2: 81-84.
Robert T. Nolte, G. Bruce Wisely, Stefan Westi, Jeffery E. Cobb, Millard H. Lambert, Riki Kurokawa, Michael. G, Rosenfeldk, Timothy. M, Willson, Christopher. K. Glass & Michael. V and Milburn. Ligand binding and co-activator Assembly of the peroxisome Proliferator-activated receptor-g. Nature 1998; 395: 137-143.
Ottana R, Maccari R, Giglio M. Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. European Journal of Medicinal Chemistry. 2011; 46: 2797-2806.
Nisheet C. Desai, Hitesh M. Satodiya, Kiran M. Rajpara, Vivek V. Joshi, Kandarp Bhatt and Hasit .V. Vaghani. Synthesis and Evaluation of N-Substituted Thiazolidine-2,4-dione Containing Pyrazole as Potent Antimicrobial Agents. Anti-Infective Agents, 2014; 12(1): 87-93.
Nguyen Tien Cong, Huynh Thi Nhan, Luong Van Hung, Tran Dinh Thang andPing-Chung Kuo. Synthesis and antibacterial activity of analogs of 5-arylidene-3-(4-methylcoumarin-7-yloxyacetylamino)-2-thioxo-1,3-thiazoli-din-4-one. Molecules 2014; 19: 13577-13586.
Nikhil M, Parekh, Krunal V and Juddhawala. Microbial studies of n-chloro aryl acetamide substituted thaizole and 2,4- Thazolidinedione derivatives. Journal of Chemical and Pharmaceutical Research, 2012; 4(9):4149-415.
Myers KA, Lambe KG, Aldridge TC, Macdonald N, Tugwood JD Amino acid residues in both the DNA-binding and ligand-binding domains influence transcriptional activity of the human peroxisome proliferator-activated receptor alpha. Biochem Biophys Res Commun. 1997; 239:522
Naresh Babu Chilamakuru, Shankarananth V, Dr Rajasekhar.K.K andTriveni Singirisetty. Synthesis, characterisation and anti-tubercular activity of some new 3,5-disubstituted-2,4-thiazolidinediones. Asian J Pharm Clin Res, 2013; 6 (5): 29-33.
Michalik L, Auwerx J, Berger J, Chatterjee V, Glass C, Gonzalez F, Grimaldi P. International Union of Pharmacology. LXI. Peroxisome proliferator activated receptors. Pharmacology Revolution. 2006; 58: 726
Madhavan G, Chakrabarti R, Reddy A. Dual PPAR? and ? activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential. Bioorganic & Medicinal Chemistry. 2006; 14: 584
Li Y, Qi Y, Huang T, Yamahara J, Roufogalis B. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPARalpha/gamma activator properties. Diabetes, Obesity & Metabolism. 2008; 10: 10
Li Q, Ayoubi A, Tailiang G. SAR studies of 3-(2-amino-ethyl)-5-(4-ethoxy benzylidene)- thiazolidine-2,4-dione as potent specific ERK 1/2 inhibitors. Bioorganic & Medicinal Chemistry letters. 2009; 19: 6042-6046.
Deepak.k.Aneja, Poonam Lohan, Sanjiv Arora, Chetan Sharma, Kamal R Aneja and Om Prakash. Synthesis of new pyrazolyl-2, 4-thiazolidinediones as antibacterial and antifungal agents. Organic and Medicinal Chemistry Letters 2011: 1-15.
Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid M (December 1997). "p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha". J. Biol. Chem. 272 (52): 33435
Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992; 68: 879
Elbrecht A, Chen Y, Cullinan C, Hayes N, Leibowitz M, Moller D. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma1 and gamma2. Biochemistry & Biophysical Resolution Community. 1996, 224, 431
Feige J, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator activated receptors are nuclear receptors at the crossroads of key cellular functions. Programme of Lipid Resolution. 2006; 45: 120
Fernanda C, Leite C, Helena R, Mourao V. Synthesis, biological evaluation and molecular modeling studies of arylidene thiazolidinediones with potential hypoglycemic and hypolipidemic activities. European Journal of Medicinal Chemistry. 2007; 42: 1263-1271.
Flavell DM, Pineda,Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, et al Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia. 2000; 43: 673
Ijpenberg, E. Jeannin, W. Wahli, B. Desvergne, Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA: a functional analysis of the malic enzyme gene PPAR response element, J. Biol. Chem. 1997; 272: 20108-20117.
Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990; 347: 645
Jones R, Barrick C, Kim A, Lindner J, Blondeau B, Fujimoto Y, Shiota M. Deletion of PPAR? in adipose tissues of mice protects against high fat diet induced obesity and insulin resistance. Proc. Natural & Acadamic Science. U.S.A. 2005; 102: 6207
Joseph-McCarthy, D. Computational approaches to structure-based ligand design. Pharmacol. Ther., 1999; 84: 179-191.
Kaczanowski S, Zielenkiewicz P. Why similar protein sequences Encode similar three M dimensional structures. Theoretical Chemistry Accounts. 2010; 125: 543
Kenny BA et al. The Application of high throughput screening to novel lead discovery, Prog. Drug Res. 1998; 41: 246-269.
Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. "Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting" J Clin Invest. 1999; 103 (11): 1489
Kersten S. "Integrated physiology and systems biology of PPAR?". Molecular Metabolism 2014; 3: 354
Khateeb J, Gantman A, Kreitenberg A, Aviram M, Fuhrman B. Paraoxonase1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: A role for PPAR gamma pathway. Atherosclerosis. 2010; 208: 119
Klebe, G. Toward a more efficient handling of conformational flexibility in computer assisted modeling of drug molecules. Persp Drug Discov Design, 1995; 3:85-105.
Klebe, G. Recent developments in structure-based drug design. J. Mol Med, 2000; 78: 269-281
Kroll T. PAX8-PPAR?1 fusion in oncogene human thyroid carcinoma. Science. 2010; 28: 1357
Lee H, Kim B, Bok J. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. European Journal of Medicinal Chemistry. 2005; 40: 862
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
- The author must submit Copyright form After acceptance of the article.
How to Cite
